1444 related articles for article (PubMed ID: 33212070)
1. MAFLD and risk of CKD.
Sun DQ; Jin Y; Wang TY; Zheng KI; Rios RS; Zhang HY; Targher G; Byrne CD; Yuan WJ; Zheng MH
Metabolism; 2021 Feb; 115():154433. PubMed ID: 33212070
[TBL] [Abstract][Full Text] [Related]
2. Metabolic dysfunction-associated fatty liver disease predicts new onset of chronic kidney disease better than fatty liver or nonalcoholic fatty liver disease.
Tanaka M; Mori K; Takahashi S; Higashiura Y; Ohnishi H; Hanawa N; Furuhashi M
Nephrol Dial Transplant; 2023 Feb; 38(3):700-711. PubMed ID: 35612975
[TBL] [Abstract][Full Text] [Related]
3. Metabolic dysfunction-associated fatty liver disease and risk of incident chronic kidney disease: A nationwide cohort study.
Jung CY; Koh HB; Park KH; Joo YS; Kim HW; Ahn SH; Park JT; Kim SU
Diabetes Metab; 2022 Jul; 48(4):101344. PubMed ID: 35346856
[TBL] [Abstract][Full Text] [Related]
4. Noninvasive fibrosis markers and chronic kidney disease among adults with nonalcoholic fatty liver in USA.
Wijarnpreecha K; Thongprayoon C; Scribani M; Ungprasert P; Cheungpasitporn W
Eur J Gastroenterol Hepatol; 2018 Apr; 30(4):404-410. PubMed ID: 29215435
[TBL] [Abstract][Full Text] [Related]
5. The association between metabolic dysfunction-associated fatty liver disease and chronic kidney disease: A systematic review and meta-analysis.
Agustanti N; Soetedjo NNM; Damara FA; Iryaningrum MR; Permana H; Bestari MB; Supriyadi R
Diabetes Metab Syndr; 2023 May; 17(5):102780. PubMed ID: 37201293
[TBL] [Abstract][Full Text] [Related]
6. Association of metabolic dysfunction-associated fatty liver disease with chronic kidney disease: a Chinese population-based study.
Hu Q; Chen Y; Bao T; Huang Y
Ren Fail; 2022 Dec; 44(1):1996-2005. PubMed ID: 36374233
[TBL] [Abstract][Full Text] [Related]
7. Association of MAFLD With Diabetes, Chronic Kidney Disease, and Cardiovascular Disease: A 4.6-Year Cohort Study in China.
Liang Y; Chen H; Liu Y; Hou X; Wei L; Bao Y; Yang C; Zong G; Wu J; Jia W
J Clin Endocrinol Metab; 2022 Jan; 107(1):88-97. PubMed ID: 34508601
[TBL] [Abstract][Full Text] [Related]
8. Effect of MAFLD on albuminuria and the interaction between MAFLD and diabetes on albuminuria.
Liu Y; Chai S; Zhang X
J Diabetes; 2024 Feb; 16(2):e13501. PubMed ID: 37974383
[TBL] [Abstract][Full Text] [Related]
9. MAFLD criteria are better than MASLD criteria at predicting the risk of chronic kidney disease.
Pan Z; Derbala M; AlNaamani K; Ghazinian H; Fan JG; Eslam M
Ann Hepatol; 2024 May; 29(5):101512. PubMed ID: 38710473
[TBL] [Abstract][Full Text] [Related]
10. MAFLD identifies patients with significant hepatic fibrosis better than NAFLD.
Yamamura S; Eslam M; Kawaguchi T; Tsutsumi T; Nakano D; Yoshinaga S; Takahashi H; Anzai K; George J; Torimura T
Liver Int; 2020 Dec; 40(12):3018-3030. PubMed ID: 32997882
[TBL] [Abstract][Full Text] [Related]
11. Association of metabolic dysfunction-associated fatty liver disease, type 2 diabetes mellitus, and metabolic goal achievement with risk of chronic kidney disease.
Su W; Chen M; Xiao L; Du S; Xue L; Feng R; Ye W
Front Public Health; 2022; 10():1047794. PubMed ID: 36420005
[TBL] [Abstract][Full Text] [Related]
12. Association between NAFLD and risk of prevalent chronic kidney disease: why there is a difference between east and west?
Zhang M; Lin S; Wang MF; Huang JF; Liu SY; Wu SM; Zhang HY; Wu ZM; Liu WY; Zhang DC; Hao CM; Zhu YY; Zheng MH; Wang XZ
BMC Gastroenterol; 2020 May; 20(1):139. PubMed ID: 32375660
[TBL] [Abstract][Full Text] [Related]
13. Association between nonalcoholic liver disease and chronic kidney disease: an ultrasound analysis from NHANES 1988-1994.
Sirota JC; McFann K; Targher G; Chonchol M; Jalal DI
Am J Nephrol; 2012; 36(5):466-71. PubMed ID: 23128368
[TBL] [Abstract][Full Text] [Related]
14. MAFLD and CKD: An Updated Narrative Review.
Mantovani A; Lombardi R; Cattazzo F; Zusi C; Cappelli D; Dalbeni A
Int J Mol Sci; 2022 Jun; 23(13):. PubMed ID: 35806010
[TBL] [Abstract][Full Text] [Related]
15. Adherence to healthy lifestyle was associated with an attenuation of the risk of chronic kidney disease from metabolic dysfunction-associated fatty liver disease: Results from two prospective cohorts.
Zhang Y; Zhang T; Liu Y; Bai S; Jiang J; Zhou H; Luan J; Cao L; Lv Y; Zhang Q; Liu L; Sun S; Wang X; Zhou M; Jia Q; Song K; Zhang H; Chang Q; Fan X; Ding Y; Chen L; Zhao Y; Niu K; Xia Y
Diabetes Metab Syndr; 2023 Oct; 17(10):102873. PubMed ID: 37804689
[TBL] [Abstract][Full Text] [Related]
16. Metabolic dysfunction-associated fatty liver disease improves detection of high liver stiffness: The Rotterdam Study.
van Kleef LA; Ayada I; Alferink LJM; Pan Q; de Knegt RJ
Hepatology; 2022 Feb; 75(2):419-429. PubMed ID: 34453359
[TBL] [Abstract][Full Text] [Related]
17. Cardiovascular and renal burdens among patients with MAFLD and NAFLD in China.
Wang Y; Yu Y; Zhang H; Chen C; Wan H; Chen Y; Xia F; Yu S; Wang N; Ye L; Lu Y
Front Endocrinol (Lausanne); 2022; 13():968766. PubMed ID: 36120461
[TBL] [Abstract][Full Text] [Related]
18. Differential Clinical Characteristics and Mortality Outcomes in Persons With NAFLD and/or MAFLD.
Nguyen VH; Le MH; Cheung RC; Nguyen MH
Clin Gastroenterol Hepatol; 2021 Oct; 19(10):2172-2181.e6. PubMed ID: 34033923
[TBL] [Abstract][Full Text] [Related]
19. The Role of Metabolic Dysfunction-Associated Fatty Liver Disease in Developing Chronic Kidney Disease: Longitudinal Cohort Study.
Wei S; Song J; Xie Y; Huang J; Yang J
JMIR Public Health Surveill; 2023 May; 9():e45050. PubMed ID: 37140958
[TBL] [Abstract][Full Text] [Related]
20. MAFLD and NAFLD in the prediction of incident chronic kidney disease.
Kwon SY; Park J; Park SH; Lee YB; Kim G; Hur KY; Koh J; Jee JH; Kim JH; Kang M; Jin SM
Sci Rep; 2023 Jan; 13(1):1796. PubMed ID: 36720976
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
